Skip to main navigation Skip to search Skip to main content

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic

  • Liesbeth Bieghs
  • , Susanne Lub
  • , Karel Fostier
  • , Ken Maes
  • , Els Van Valckenborgh
  • , Eline Menu
  • , Hans E Johnsen
  • , Michael T Overgaard
  • , Olle Larsson
  • , Magnus Axelson
  • , Mette Nyegaard
  • , Rik Schots
  • , Helena Jernberg-Wiklund
  • , Karin Vanderkerken
  • , Elke De Bruyne

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

The ABT-analogous 737, 263 and 199 are BH3 mimetics showing potent anti-myeloma (MM) activity, but only on defined molecular subgroups of MM patients presenting a Bcl-2high/Mcl-1low profile. IGF-1 is a major survival factor in MM regulating the expression of Bcl-2 proteins and might therefore be a resistance factor to these ABT-analogous. We first show that IGF-1 protected human MM cell lines (HMCLs) against ABT-737. Concurrently, the IGF-1 receptor inhibitor picropodophyllin (PPP) synergistically sensitized HMCL, primary human MM and murine 5T33MM cells to ABT-737 and ABT-199 by further decreasing cell viability and enhancing apoptosis. Knockdown of Bcl-2 by shRNA protected MM cells to ABT-737, while Mcl-1 shRNA sensitized the cells. PPP overcame the Bcl-2 dependency of ABT-737, but failed to completely overcome the protective effect of Mcl-1. In vivo, co-treatment of 5T33MM bearing mice significantly decreased tumor burden and prolonged overall survival both in a prophylactic and therapeutic setting. Interestingly, proteasome inhibitor resistant CD138- 5T33MM cells were more sensitive to ABT-737, whereas PPP alone targeted the CD138+ cells more effectively. After co-treatment, both subpopulations were targeted equally. Together, the combination of an IGF-1R inhibitor and an ABT-analogue displays synergistic anti-myeloma activity providing the rational for further (pre)clinical testing.

Original languageEnglish
JournalOncoTarget
Volume5
Issue number22
Pages (from-to)11193-11208
Number of pages16
ISSN1949-2553
Publication statusPublished - 30 Apr 2014

Fingerprint

Dive into the research topics of 'The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic'. Together they form a unique fingerprint.

Cite this